NICE backs AZ’s Forxiga for heart failure

Just a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE for this use by the NHS in England and Wales.

AZ’s Forxiga gets heart claim data on its EU label

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian c...

First-in-class diabetes drug recommended for FDA approval

AstraZeneca and Bristol-Myers Squibb have received a positive opinion from an FDA committee for dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor developed through an allian